Objective:

To evaluate the real-world use of anti-CGRP therapies in terms of effectiveness, tolerability, barriers to access, and treatment adherence among migraine patients in Egypt.

Approach:

Key Findings:

• 68% of patients showed a favorable ≥50% response to treatment.
• Clinically significant reductions in monthly migraine days, headache severity, duration, HIT-6, and MIDAS scores were observed (p < 0.001).
• Tolerability of anti-CGRP therapies was generally favorable.
• Treatment discontinuation occurred in 35 patients, primarily due to satisfactory improvement, lack of improvement, or cost.
• Relapse occurred in 42.1% of cases after treatment discontinuation.

Interpretation:

The study provides insights into the effectiveness and tolerability of anti-CGRP therapies in an Egyptian cohort, while also highlighting challenges related to access and adherence.

Limitations:

• Observational design limits the ability to establish causality.
• Further controlled studies are warranted to validate findings.

Conclusion:

The study demonstrates consistent clinical improvement and good tolerability of anti-CGRP therapies among migraine patients in Egypt, alongside significant access challenges.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.